Avoro Capital Advisors LLC Fennec Pharmaceuticals Inc. Transaction History

Avoro Capital Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.89 - $10.01 $1.83 Million - $4.7 Million	-470,000 Reduced 28.14%	1,200,000 $5.28 Million
Q2 2020 Aug 14, 2020	BUY	$5.43 - $9.39 $3.06 Million - $5.3 Million	564,001 Added 50.99%	1,670,000 $13.9 Million
Q4 2018 Feb 14, 2019	BUY	$5.37 - $8.39 $447,498 - $699,163	83,333 Added 8.15%	1,105,999 $7.06 Million
Q2 2018 Aug 14, 2018	BUY	$10.05 - $14.33 $7.54 Million - $10.7 Million	750,000 Added 275.06%	1,022,666 $10.7 Million
Q1 2018 May 15, 2018	BUY	$8.26 - $12.1 $550,661 - $806,658	66,666 Added 32.36%	272,666 $3.28 Million
Q4 2017 Feb 14, 2018	BUY	$8.9 - $12.35 $1.24 Million - $1.72 Million	139,334 Added 209.0%	206,000 $2.73 Million
Q3 2017 Nov 14, 2017	BUY	$11.09 - $12.0 $739,325 - $799,992	66,666	66,666 $731,000

14.7M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $165M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.